Breaking News

Russell 2000 Small-Stock Index Falls 10% From Record Closing High in March
Tweet TWEET

ACADIA Pharmaceuticals Added to Russell 2000 Index

  ACADIA Pharmaceuticals Added to Russell 2000 Index

Business Wire

SAN DIEGO -- July 1, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today announced
that it has been added to the Russell 2000 Index effective after the close of
market on Friday, June 28, 2013, as part of Russell Investments’ annual index
reconstitution. ACADIA also was added to the Russell 3000 and Russell Global
Indexes.

The annual reconstitution of the Russell 3000 captures the 3,000 largest U.S.
stocks as of the end of May, ranking them by total market capitalization. The
largest 1,000 companies in this ranking make up the Russell 1000 and the next
2,000 companies comprise the Russell 2000. The Russell 3000 also serves as the
U.S. component to the Russell Global Index. Russell indexes are widely used by
investment managers and institutional investors for index funds and as
benchmarks for passive and active investment strategies. Approximately $4.1
trillion in assets are benchmarked to the Russell indexes. For more
information about Russell indexes, visit: http://www.russell.com/indexes/.

About Russell Investments

Russell Investments (Russell) is a global asset manager and one of only a few
firms that offers actively managed multi-asset portfolios and services that
include advice, investments and implementation. Russell stands with
institutional investors, financial advisors and individuals working with their
advisors—using the firm’s core capabilities that extend across capital market
insights, manager research, portfolio construction, portfolio implementation
and indexes to help each achieve their desired investment outcomes.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two
advanced preclinical programs directed at Parkinson’s disease and other
neurological disorders. All product candidates are small molecules that
emanate from discoveries made at ACADIA. ACADIA maintains a website at
www.acadia-pharm.com to which ACADIA regularly posts copies of its press
releases as well as additional information and through which interested
parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the progress and timing of ACADIA’s drug discovery
and development programs, either alone or with a partner, including clinical
trials, and the benefits to be derived from ACADIA’s product candidates, in
each case including pimavanserin. These statements are only predictions based
on current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that past
results of clinical trials may not be indicative of future trial results. For
a discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December31, 2012 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this cautionary
statement and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except as
required by law.

Contact:

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
Lisa Barthelemy, Director of Investor Relations
(858) 558-2871
 
Press spacebar to pause and continue. Press esc to stop.